Jenny Furlanetto

Martin Behaim Str. 12
Neu Isenburg, HE 63263, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.

Journal: ESMO open

Published: December 19, 2023

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial.

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 13, 2023

Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.

Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.

Journal: Future oncology (London, England)

Published: September 07, 2022

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE).

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE).

Journal: ESMO open

Published: August 03, 2022

Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].

Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 20, 2022

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 18, 2022

Evolution of synchronous female bilateral breast cancers and response to treatment.

Evolution of synchronous female bilateral breast cancers and response to treatment.

Journal: Nature medicine

Published: February 08, 2022

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer.

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: July 09, 2021

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 08, 2021

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

Journal: The Lancet. Oncology

Published: March 25, 2021

Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.

Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 05, 2021

Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial.

Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 04, 2021

Showing 1-12 of 39

Last Updated: 09/26/2026